HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
Publication/Presentation Date
1-1-2018
Abstract
In the RV144 vaccine trial, IgG responses against the HIV envelope variable loops 1 and 2 (V1V2) were associated with decreased HIV acquisition risk. We previously reported that infants immunized with an MF59-adjuvanted rgp120 vaccine developed higher-magnitude anti-V1V2 IgG responses than adult RV144 vaccinees. To determine whether the robust antibody response in infants is due to differences in vaccine regimens or to inherent differences between the adult and infant immune systems, we compared Env-specific IgG responses in adults and infants immunized with the same MF59- and alum-adjuvanted HIV envelope vaccines. At peak immunogenicity, the magnitudes of the gp120- and V1V2-specific IgG responses were comparable between adults and infants immunized with the alum/MNrgp120 vaccine (gp120 median fluorescence intensities [FIs] in infants = 7,118 and in adults = 11,510,
Volume
92
Issue
1
ISSN
1098-5514
Published In/Presented At
McGuire, E. P., Fong, Y., Toote, C., Cunningham, C. K., McFarland, E. J., Borkowsky, W., Barnett, S., Itell, H. L., Kumar, A., Gray, G., McElrath, M. J., Tomaras, G. D., Permar, S. R., & Fouda, G. G. (2017). HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine. Journal of virology, 92(1), e01070-17. https://doi.org/10.1128/JVI.01070-17
Disciplines
Diagnosis | Medicine and Health Sciences | Other Analytical, Diagnostic and Therapeutic Techniques and Equipment | Radiology
PubMedID
29021402
Department(s)
Department of Radiology and Diagnostic Medical Imaging
Document Type
Article